Consonance Capital Management LP Exelixis, Inc. Transaction History

Consonance Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $130 Million - $165 Million	-6,645,113 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $37.8 Million - $60.3 Million	2,766,063 Added 71.31%	6,645,113 $131 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $10.6 Million - $15 Million	669,850 Added 20.87%	3,879,050 $68.7 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $59.6 Million - $72 Million	3,209,200 New	3,209,200 $69.1 Million

481

244M

1.92M

1.4M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.